Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) faces concerns about patient conversion to new treatments, affecting operating margins. RBC Capital lowered the price target to $420 but believes the cystic fibrosis franchise remains strong. The company may need better execution to justify its valuation.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing